 To answer this important question, the investigators propose to perform an international multicenter randomized study with the aim of comparing EUS-FNB with ROSE versus EUS-FNB without ROSE using three novel needles the 20-gauge ProCoreTM, the 22-gauge SharkCoreTM and the 22-gauge AcquireTM needle in patients with solid pancreatic masses. These needles have become recently available and preliminary results for both pancreatic and non-pancreatic lesions are extremely encouraging Indeed, all these needles demonstrated a very high accuracy rate 92. Each center involved in the present study must have at least 2 of the 3 needles available. The non-inferiority design of the study will test the investigators hypothesis that EUS-FNB, by providing adequate samples for histologic examination, will perform at least as good as EUS-FNB with ROSE. The choice of the 20G ProCore TM, the 22G SharkCoreTM or 22G AcquireTM, instead of the 25G or the 19G, balances the need to use a needle that acquires enough tissue to perform all the studies needed to reach the definitive diagnosis, with its usability, i.e. a needle that can be used by most, if not all the endosonographers and not only by the experts. In this regards, the 25-gauge seems too small to gather enough tissue in a consistent number of patients while the 19-gauge is less maneuverable and more difficult to use thus preventing its utilization by all endosonographers. 